Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $56.57.

A number of analysts have recently weighed in on AGIO shares. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 price target for the company. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th.

Agios Pharmaceuticals Trading Down 4.8 %

Shares of NASDAQ:AGIO opened at $30.76 on Friday. The firm has a 50 day simple moving average of $33.29 and a 200-day simple moving average of $41.11. Agios Pharmaceuticals has a twelve month low of $27.14 and a twelve month high of $62.58. The company has a market capitalization of $1.76 billion, a PE ratio of 2.71 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities research analysts predict that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals in the fourth quarter valued at $33,000. GF Fund Management CO. LTD. purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $39,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals in the 4th quarter worth about $53,000. Sterling Capital Management LLC grew its holdings in Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares during the period. Finally, Quest Partners LLC increased its position in shares of Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,283 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.